Cytek Biosciences (CTKB) Other Accumulated Expenses (2020 - 2026)

Cytek Biosciences' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $22.2 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 72.74% year-over-year to $22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (up 72.74% YoY) and the FY2025 annual result came in at $17.0 million, up 25.82% from the prior year.
• Other Accumulated Expenses was $22.2 million for Q1 2026 at Cytek Biosciences, up from $17.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $22.2 million in Q1 2026 and bottomed at $4.9 million in Q3 2022.
• A 5-year average of $10.8 million and a median of $8.4 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 316.73% — and 2024, when it retreated 24.24%.
• Cytek Biosciences' Other Accumulated Expenses stood at $8.0 million in 2022, then retreated by 0.72% to $7.9 million in 2023, then jumped by 70.75% to $13.5 million in 2024, then advanced by 25.82% to $17.0 million in 2025, then jumped by 30.6% to $22.2 million in 2026.
• Business Quant data shows CTKB's Other Accumulated Expenses at $22.2 million in Q1 2026, $17.0 million in Q4 2025, and $16.4 million in Q3 2025.